- For in vitro testing and laboratory use only.
- Not for human or animal consumption.
- Bodily introduction is illegal.
- Handle only by licensed professionals.
- Not a drug, food, or cosmetic.
- Educational use only.
Quick take on Selank
Selank is a synthetic heptapeptide developed in the 1990s by the Russian Academy of Medical Sciences as a modified analog of tuftsin — a natural immunomodulatory peptide produced by the spleen. Russian researchers added four extra amino acids (Pro-Gly-Pro) to stabilize the molecule and extend its half-life, creating a compound that crosses the blood-brain barrier and acts on the central nervous system. It's approved in Russia as an anxiolytic medication and has been in clinical use there since 2009, primarily for generalized anxiety disorder.
Mechanism in plain English
Selank hits several systems simultaneously, which is part of why its effects are hard to pin down to one mechanism. It modulates the GABA-ergic system (similar target to benzodiazepines, but without the receptor binding and dependence profile), influences serotonin and dopamine pathways, upregulates BDNF (brain-derived neurotrophic factor), and modulates enkephalin metabolism by inhibiting enkephalin-degrading enzymes. The result is anxiolytic, mild nootropic, and mood-stabilizing effects without sedation.
What it's used for
People take it for anxiety reduction without sedation, cognitive clarity under stress, and stable mood. First effects often show up within 15-30 minutes of dosing and can last several hours. Many users describe the feeling as "the anxiety just isn't there anymore," without any dulling or brain fog — you're still sharp, just calmer.
Upsides and downsides
Main upside — anxiolytic effect without sedation, tolerance, or withdrawal. In Russian clinical data, Selank performed comparably to benzodiazepines for anxiety scores but without the cognitive impairment, dependence potential, or rebound anxiety that make benzos a long-term problem.
Main downside — the evidence base is almost entirely Russian, and modern Western replication is thin. You're trusting a specific research lineage rather than global consensus.
Typical protocol
Protocols use intranasal administration (which is how it's clinically delivered in Russia) at 250-500 mcg per dose, 1-3 times per day, in cycles of 2-4 weeks. Subcutaneous injection also works but offers no clear advantage over the nasal route for this peptide.
Who should skip it
- Pregnant or breastfeeding women.
- Anyone on MAO inhibitors.
Regulatory status
Not on WADA's prohibited list — no performance-enhancing effects. Not approved as a medication outside Russia; sold as a research peptide internationally.
In the 1970s, researchers noticed something unexpected about the immune system's messenger peptides. A small fragment cleaved from immunoglobulin G — the most abundant antibody in human blood — turned out to have effects far beyond immunity. This four-amino-acid peptide, named tuftsin (after Tufts University where it was discovered), was found to cross into the brain and influence mood, anxiety, and cognition.
The problem was classical: tuftsin has a half-life of seconds in circulation. It's destroyed almost immediately by peptidase enzymes. Useless as a drug.
Russian researchers at the Institute of Molecular Genetics in Moscow decided to fix this. They took tuftsin's four-amino-acid core (Thr-Lys-Pro-Arg) and added three proline-rich amino acids (Pro-Gly-Pro) at the C-terminus — a structure that dramatically increases stability against enzymatic degradation. The result was a synthetic heptapeptide called Selank.
Unlike most Russian peptide discoveries that quietly collect citations and never leave the lab, Selank actually went through clinical trials, got approved, and is sold at pharmacies in Russia and some post-Soviet states as an intranasal anxiolytic medication. It's one of very few peptides covered on this blog with actual regulatory approval anywhere in the world — just not in the regions most readers live.
Selank: what it is and how it works in a nutshell
Selank is a synthetic heptapeptide (sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin. It was developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the V.V. Zakusov Research Institute of Pharmacology. The lead researchers associated with its development were Ivan Ashmarin, Nikolai Myasoedov, and Sergei Seredenin [1].
Selank is approved by Russia's Federal Supervision Agency for Use of Healthcare as an intranasal anxiolytic medication, sold under the brand name Selank as a 0.15% nasal solution. It's used clinically in Russia for generalized anxiety disorder and neurasthenia. It is not FDA-approved in the United States and has no approved status in the EU, but it's been actively studied in Russian clinical research since the late 1990s.
This regulatory status is genuinely unusual — most peptides covered on this blog are either fully unapproved anywhere, or FDA-approved for a specific narrow indication. Selank occupies a rare middle position: approved medicine in its country of origin, research chemical elsewhere.
Selank mechanism of action: what it actually does in the body
This is where Selank gets interesting. It doesn't work through a single clean receptor mechanism. Instead, it affects multiple neurotransmitter systems simultaneously — which is also why characterizing it as "the anti-anxiety peptide" undersells what it actually does.
GABAergic modulation (the anxiolytic effect).
Selank appears to enhance GABAergic tone — GABA being the brain's primary inhibitory neurotransmitter and the target of every benzodiazepine ever made. But Selank doesn't bind GABA-A receptors directly the way benzodiazepines do. Instead, it appears to act as an allosteric modulator of the GABA-A receptor complex, changing the number of GABA binding sites without altering binding affinity [2].
Volkova et al. (2016) showed that Selank administration alters expression of genes involved in GABAergic neurotransmission — Drd1a, Drd2, Slc6a13, and Ptgs2 — suggesting the effect is at least partly transcriptional [3]. This matters because it means Selank's anxiolytic effect develops through modulation of how the GABA system functions overall, rather than direct channel opening like benzodiazepines.
The practical consequence: benzodiazepine-like anxiety reduction without sedation, without motor impairment, and without the dependence/withdrawal liability that makes benzos such problematic long-term medications.
Monoaminergic effects (the nootropic effect).
Selank influences serotonin, dopamine, and norepinephrine levels in the brain. Research in rats shows it increases serotonin turnover and metabolism [4]. Other studies show dopamine effects contributing to improved attention, motivation, and learning. The combined effect on these three monoamines produces a mild stimulant-like cognitive enhancement without the agitation of actual stimulants.
BDNF upregulation.
Selank rapidly elevates brain-derived neurotrophic factor (BDNF) expression in the hippocampus [5]. BDNF is critical for neuroplasticity, memory, and learning. This is part of why Selank shows cognitive-enhancing effects and may protect against age-related memory decline.
Enkephalin system interaction.
Both Selank and its sister peptide Semax have been shown to inhibit enzymes involved in breaking down enkephalins — the body's endogenous opioid-like peptides. This indirectly potentiates enkephalin activity, which may contribute to mood elevation and stress resilience.
Immune modulation (the tuftsin inheritance).
Because Selank is derived from tuftsin, it retains some of its parent peptide's immune effects. It modulates interleukin-6 (IL-6) expression, affects T-helper cell cytokine balance, enhances phagocytic activity of macrophages, and influences immune cells that express tuftsin receptors (macrophages, microglia) [1]. This neuroimmune bridge is pharmacologically unique among anxiolytics.
Pharmacokinetics. Selank has a very short half-life in circulation (minutes), but its effects last much longer — presumably because the peptide triggers downstream changes (gene expression, BDNF elevation, receptor state changes) that outlast the molecule itself. Typical clinical effects from a single intranasal dose last 4-8 hours.
Who uses Selank and what for
- People with generalized anxiety disorder (GAD) or chronic anxiety — the core use case and the Russian approved indication. Users often describe a sense of calm without sedation.
- People with anxiety-related cognitive fog — the combination of anxiolytic and nootropic effects is unusual and specifically helpful for people whose anxiety impairs their thinking.
- Those seeking alternatives to benzodiazepines — Selank's main clinical advantage over benzos: no sedation, no tolerance, no dependence, no withdrawal (documented in repeated clinical studies [6]).
- People with mild-to-moderate depression with anxiety features — adjunctive use alongside antidepressants in some clinical settings.
- Students, professionals, executives — nootropic use for stress-resilient cognitive performance.
- Post-stressful event recovery — integrated into protocols for recovering from trauma, burnout, or chronic stress.
Realistic expectations: anxiety reduction within 30-60 minutes of intranasal dose, improved cognitive clarity especially for tasks blocked by anxiety, better emotional regulation, gradual improvement in overall stress resilience with regular use. Most users report the effect as "feeling normal but calmer" rather than "feeling drugged."
What WON'T happen: dramatic euphoria (not a mood-altering compound), quick fix for severe depression or panic disorder (Selank is for anxiety, not crisis-level mental illness), sedation that could help with sleep issues specifically (it's non-sedating by design), replacement for medication in severe psychiatric conditions.
Important framing honesty: most clinical trial data comes from Russian research institutions, with limited independent international replication. The effects are real and the Russian approval process isn't trivial, but Western pharmacology has not fully validated this peptide through independent trials. This matters for anyone forming their expectations.
What Selank stacks with: popular combinations
- Selank + Semax — the classic Russian neuropeptide stack. Semax (developed by the same lab) is more cognitive-stimulating; Selank is more anxiolytic. Together they provide focus + calm. Most commonly used in learning and performance contexts.
- Selank + BPC-157 — for stress-associated GI issues. Selank handles the central anxiety component; BPC-157 handles the peripheral GI inflammation from chronic stress.
- Selank + SSRI/SNRI — used adjunctively with antidepressants in some clinical protocols, though interaction caution is warranted.
- Selank + L-theanine + magnesium — stacking with mild GABAergic supplements for enhanced anxiolysis. Used by biohackers seeking a stronger calming effect.
Generally avoided with: strong GABAergic drugs (benzodiazepines, alcohol, Z-drugs) — additive effects possible, though Selank's mechanism is indirect so the interaction is milder than expected.
Selank side effects and risks
One of the cleanest side effect profiles of any peptide covered on this blog, based on both Russian clinical trial data and decades of real-world Russian clinical experience.
Reported in clinical studies and real-world use:
- Mild headache — occasionally, especially first few doses
- Transient nasal irritation (with intranasal formulation) — resolves quickly
- Very mild fatigue — rare, typically resolves
- Mild dizziness — uncommon
- Injection site reactions — with subcutaneous use, minor
What's NOT reported — and this is the clinically important part:
- No sedation
- No cognitive impairment
- No dependence or tolerance — documented across multiple studies of chronic use
- No withdrawal syndrome
- No impairment of motor function, memory, or coordination
Who should be cautious or avoid:
- Pregnant or breastfeeding women (no safety data)
- People with severe psychiatric conditions (schizophrenia, bipolar disorder) — poorly studied in these populations
- Anyone with severe allergies to components of the formulation
- Children — not studied adequately in pediatric populations
The honest regulatory status: Selank is approved in Russia but not in the US, EU, UK, or most other Western jurisdictions. This isn't just paperwork — it means independent safety validation by those regulators hasn't been completed. The Russian approval is real but doesn't carry the same weight as FDA/EMA approval in terms of global pharmacological validation.
How to use and store Selank
Russian approved formulation: 0.15% intranasal solution. Standard dosing: 2-3 drops per nostril, 2-3 times daily, for courses of 14 days. Courses can be repeated after breaks.
Off-label protocols commonly used:
- Intranasal: 250-750 mcg per dose, 1-3 times daily (similar pattern to Russian protocols)
- Subcutaneous: 250-500 mcg per injection, 1-2 times daily
- Cycle: 2-4 weeks typical, followed by break of 1-2 weeks
- Timing: can be taken anytime — morning and midday most common, avoid right before bed (stimulating for some)
Why intranasal makes sense: peptides this small can cross the cribriform plate at the top of the nasal cavity and enter the brain directly, partially bypassing the blood-brain barrier. This is more efficient for central nervous system peptides than subcutaneous injection.
Storage: lyophilized form in freezer at -20°C. Reconstituted solution refrigerated at 2-8°C, used within 21-30 days. The Russian pharmaceutical formulation has specific stability and storage requirements per manufacturer.
Selank vs alternatives: what's different
- Benzodiazepines (alprazolam, diazepam, lorazepam) — faster acting, more potent short-term, but cause sedation, cognitive impairment, dependence, and withdrawal. Appropriate for acute panic, not chronic anxiety management.
- SSRIs/SNRIs (sertraline, escitalopram, venlafaxine) — first-line for chronic anxiety disorders, 4-6 weeks to onset, real side effect profile (sexual, weight, emotional blunting). Different mechanism, longer-term framework.
- Buspirone — non-benzodiazepine anxiolytic, works on serotonin receptors. Similar "non-sedating" positioning as Selank, but different mechanism, less cognitive-enhancing.
- Semax — sister Russian peptide, more cognitive-stimulating and less anxiolytic. Often stacked with Selank rather than used as substitute.
- L-theanine, magnesium, ashwagandha — natural alternatives with mild effects. Lower potency but very safe and widely available.
Selank's distinguishing feature: anxiolytic efficacy comparable to benzodiazepines in clinical trials, combined with cognitive enhancement and without the sedation/dependence profile. For people who need anxiety management but can't afford cognitive impairment or dependence risk, this combination is genuinely unique.
Myths about Selank
- "Selank is a Russian military secret peptide." Selank was developed by civilian research institutes (Institute of Molecular Genetics, Zakusov Institute of Pharmacology), went through normal clinical trials, and is available at regular Russian pharmacies. The "secret military peptide" framing sometimes used in marketing is fiction.
- "Selank has no side effects and is completely safe for unlimited use." Selank's side effect profile is genuinely clean compared to benzodiazepines, but "no side effects" is marketing language. Long-term Western clinical trials in large populations haven't been completed. The available safety data is real but not exhaustive. Treating any compound as "completely safe for unlimited use" is poor risk management.
Sources
- Zozulya, A. A., Neznamov, G. G., Syunyakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Y., Serebryakova, E. V., Siranchieva, O. A., Andryushenko, A. V., Telechova, E. S., Lyapina, L. A., Myasoedov, N. F., & Seredenin, S. B. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 108(4), 38-48. https://pubmed.ncbi.nlm.nih.gov/18454096/ — foundational clinical trial comparing Selank to medazepam in 62 patients with GAD and neurasthenia.
- Kozlovskii, I. I., & Danchev, N. D. (2002). Optimizing action of synthetic peptide Selank on active avoidance conditioning test in rats. Zhurnal Vysshei Nervnoi Deyatel'nosti Imeni I P Pavlova, 52, 579-584. — foundational behavioral pharmacology work on Selank's anxiolytic mechanism.
- Volkova, A., Shadrina, M., Kolomin, T., Andreeva, L., Limborska, S., Myasoedov, N., & Slominsky, P. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology, 7, 31. https://www.frontiersin.org/articles/10.3389/fphar.2016.00031/full — documents gene expression changes linking Selank to GABAergic system.
- Andreeva, L. A., Nagaev, I. Y., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2005). Psychotropic effects of Selank and its influence on the content of monoamines and their metabolites in the brain structures of rats. Bulletin of Experimental Biology and Medicine, 140(4), 482-484. — documents Selank's effects on serotonin, dopamine, and noradrenaline metabolism.
- Kolik, L. G., Nadorova, A. V., Antipova, T. A., Kruglov, S. V., Kudrin, V. S., & Durnev, A. D. (2019). Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bulletin of Experimental Biology and Medicine, 167, 641-644. https://link.springer.com/article/10.1007/s10517-019-04588-9 — documents BDNF-related neuroprotective effects.
- Teleshova, E. S., Bochkarev, V. K., Syunyakov, T. S., Bugaeva, T. P., & Neznamov, G. G. (2010). Results of clinical and pharmacological studies of peptide anxiolytic Selank. Psikhiatriya, 4, 26-35. — clinical-pharmacological trial of Selank in anxiety disorders documenting tolerance and safety profile.
- Ashmarin, I. P., Lelekova, T. V., & Sanzhieva, L. Ts. (2005). [The role of regulatory peptides in the integrative functions of the organism]. Bulletin of Experimental Biology and Medicine, 139, 453-458. — foundational context on regulatory peptides including Selank and Semax from the lead Russian researchers.
- Sollertinskaya, T. N., Shorokhov, M. V., Kamenskii, A. A., Levitskaya, N. G., Zolotarev, Yu. A., Andreeva, L. A., Alfeeva, L. Y., Yatskovskaya, N. E., & Myasoedov, N. F. (2008). Compensatory and antiamnestic effects of heptapeptide Selank in monkeys. Journal of Evolutionary Biochemistry and Physiology, 44, 332-340. — primate data on cognitive effects supporting cross-species translation.
Selank Dosage Guide
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed in Russia as a stable analog of the endogenous immunomodulatory peptide tuftsin, extended with a Pro-Gly-Pro C-terminal sequence to enhance metabolic stability. It produces anxiolytic effects comparable to benzodiazepines by modulating GABA-A receptors and influencing serotonin, dopamine, and BDNF expression — but without sedation, cognitive impairment, tolerance, or withdrawal. This guide is aimed at users seeking anxiety relief without benzodiazepine side effects, individuals managing neurasthenia or stress-related asthenia, and those exploring nootropic stacks with Semax. Dosing below combines the Russian clinical approval protocols (Selank 0.15% nasal spray, 2009 onward), the Zozulya et al. GAD trials comparing Selank to medazepam, and Dr. William Seeds' community subcutaneous protocols.
Real-World Dosage Protocols by Experience Level
| Experience Level | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner (SC) | 150 mcg | Once daily, SC | Titrate by 50 mcg/week up to 300 mcg |
| Standard (SC) | 250 mcg | Once daily, SC | Most common community injectable dose |
| Intermediate (SC) | 300–500 mcg | Once daily, SC | Upper injection range |
| Beginner (intranasal) | 250–300 mcg | 1–2 times daily, IN | 1–2 sprays of 0.15% formulation |
| Russian clinical protocol | 250–300 mcg | 3 times daily, IN, 14 days | Zozulya GAD trial reference |
| Upper intranasal | 600–900 mcg | Split across 2–3 doses daily, IN | 750–1000 mcg/day per Seeds protocol |
Doses also shift depending on the specific goal. The same peptide used for acute anxiety versus ongoing neurasthenia or cognitive support can follow quite different protocols.
Dosage by Goal
| Goal | Recommended Dose | Frequency | Cycle Length |
|---|---|---|---|
| Generalized anxiety | 250–300 mcg | 2–3 times daily, IN | 14 days on / 14 days off |
| Acute anxiety / high-stress days | 250–500 mcg | As needed, IN | On-demand |
| Neurasthenia / chronic stress | 300 mcg | 3 times daily, IN | 14-day course |
| Cognitive support / nootropic | 250 mcg | Once daily AM, IN or SC | 2–4 weeks on / 2–4 weeks off |
| Stacked with Semax | 250 mcg Selank + 300 mcg Semax | Staggered 15–30 min apart, IN | 2–4 weeks |
| Opioid withdrawal adjunct (preclinical) | 300 mcg/kg equivalent | 2–3 times daily, IN | Short-term |
Intranasal is the clinically validated route — Russian studies used the 0.15% nasal formulation with 92.8% bioavailability and CNS penetration via the olfactory pathway, partially bypassing the blood-brain barrier. Subcutaneous injection works, but you're using it outside the evidence base that established Selank's anxiolytic profile, so start there only if nasal irritation or chronic sinus issues rule out the spray. Effects typically appear within 10–20 minutes and last 6–24 hours, with no loss of acuity from dose to dose — unlike benzodiazepines, there's no documented tolerance, dependence, or withdrawal even in Russian clinical populations treated since 2009. Cycling 14 days on / 14 days off mirrors the clinical protocol; continuous long-term daily use is relatively uncharted territory outside Russia.
Selank Storage Guide: How to Keep Your Research Peptide Stable and Effective
Selank ships as a white lyophilized powder in a sealed glass vial, freeze-dried to preserve its heptapeptide structure and extend its shelf life. With a few simple habits — cold, dark, dry — the sealed vial stays in perfect condition for its full shelf life. Here's exactly how to store it.
Lyophilized Powder (Unreconstituted)
| Parameter | Details | Notes |
|---|---|---|
| Storage Temperature | Freezer at −20°C (−4°F) for long-term storage up to 24 months. Refrigeration at 2–8°C (36–46°F) is fine for short-term use up to ~3 months. | Original sealed vial in the freezer is the safest default. |
| Light Sensitivity | Yes — protect from direct light and UV exposure to prevent photodegradation. | Keep in the original box or an opaque, amber container. |
| Freezing | Allowed and recommended. −20°C is standard for long-term storage; −80°C extends stability further if available. | Freeze from the start if you won't use it within 3 months. |
| Signs of Degradation | Healthy powder is white to off-white and loose or cake-like. Watch for yellowing, clumping, visible moisture, or a sticky texture — the basic residues in Selank can attract humidity if the seal is broken. | Any color change, clumping, or moisture = discard the vial. |
| Common Mistakes | Leaving the vial at room temperature after delivery, storing in a humid kitchen or bathroom, or opening a cold vial and letting condensation form inside. | Put it in the freezer on arrival, and let sealed vials warm to room temperature before opening. |
Shipping & Product Authenticity
Every order is processed quickly and shipped with full tracking. All products come directly from the official Generic Peptides supply chain — in original manufacturer packaging, carefully handled from warehouse to your door.
Shipping Times
| Destination | Delivery Time | Notes |
|---|---|---|
| USA Domestic | 4–5 business days | Faster when local warehouse stock is selected at checkout |
| International | 13–15 business days | Tracking included; update frequency may vary by destination country |
| Order Processing | 24–48 business hours | Processing begins after payment confirmation |
| Tracking | Provided on all orders | Tracking number sent after dispatch; multiple warehouses may result in separate shipments |
Direct Supply & Secure Delivery
This product is supplied through the official Generic Peptides distribution chain and shipped in original manufacturer packaging. Orders are packed securely to protect the contents during transit and to respect customer privacy as a standard practice.
Outer packaging is neutral and does not display product details on the exterior — a common approach to protect shipments from damage, tampering, and unnecessary exposure during delivery.
What to Expect
- Orders are processed after payment confirmation
- USA domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity & Verified Supply
Every order includes full authenticity assurance: official Generic Peptides presentation, batch-linked lab documentation, and sealed original packaging — giving customers confidence in every purchase.
| Authenticity Feature | Details |
|---|---|
| Packaging | Original manufacturer packaging — sealed and unaltered |
| Lab Documentation | Batch-linked certificate of analysis available on request |
| Supply Chain | Sourced exclusively through official Generic Peptides distribution |
Shipping & Returns
Selank is a synthetic heptapeptide (a chain of seven amino acids) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s. It was engineered by modifying tuftsin — a naturally occurring immune-modulating peptide — with three additional amino acids to make it more stable and allow it to cross the blood-brain barrier. In Russia and several CIS countries, Selank has been approved since the early 2000s as a prescription treatment for generalized anxiety disorder and neurasthenia. In the US, EU, UK, and most Western countries, it is sold only as a research chemical and is not FDA-approved.
Selank works through multiple neurotransmitter systems rather than a single pathway. Its primary anti-anxiety effect comes from modulating GABA-A receptors — similar to how benzodiazepines work, but without producing sedation or dependence. It also increases levels of serotonin and dopamine, enhances expression of brain-derived neurotrophic factor (BDNF) in the hippocampus, and modulates enkephalins (the body's natural opioid-like peptides). This multi-target action is why Selank reduces anxiety while also supporting focus, memory, and mood without the brain fog that classic anti-anxiety medications often produce.
The primary research-backed benefits are reduced anxiety, improved stress resilience, sharper focus, better short-term memory, and a stable, calm mood. Russian clinical trials showed Selank produced anxiolytic effects comparable to diazepam (Valium) but without sedation, tolerance, or withdrawal. Users commonly report feeling calmer but more mentally clear, an uncommon combination. Some research also points to mild immune-modulating effects inherited from its tuftsin origin, potentially helping with recovery from viral infections. Long-term human safety data outside Russia remains limited.
Common protocols use 250 to 500 mcg administered intranasally, once or twice per day, though some research doses go up to 900 mcg. Intranasal delivery is preferred because peptides pass more efficiently into the brain through the nasal mucosa than through subcutaneous injection. Russian clinical use often involves 14-day courses followed by breaks. These are research and clinical protocols — there are no officially approved dosing guidelines in the US or EU.
Many users notice effects within the first dose — typically within 15 to 30 minutes of intranasal administration, with peak effects around 1 to 2 hours. The immediate effect is usually a subtle reduction in anxious thoughts and a sense of calm clarity, rather than a dramatic sedation. Cumulative benefits for chronic anxiety and mood tend to emerge over 1–3 weeks of consistent use. Unlike SSRIs, there's no long waiting period before it starts working, and unlike benzodiazepines, the effect doesn't feel like being medicated.
Selank has an unusually clean safety profile in the available research. The most commonly reported side effects are mild and include brief nasal irritation from the spray, occasional headache, fatigue, and mild dizziness. In Russian clinical trials involving thousands of patients, no significant adverse events, withdrawal symptoms, or tolerance were reported even with extended use. That said, long-term safety data in Western populations is scarce, and there is always some uncertainty with research peptides, particularly around purity and manufacturing quality.
Current evidence suggests Selank is not addictive and does not produce tolerance or physical dependence — this is one of its most notable advantages over benzodiazepines. Russian studies have specifically shown that discontinuing Selank does not produce withdrawal symptoms or rebound anxiety. The GABA modulation appears to work through a different mechanism than classic benzodiazepines, which is likely why the dependence profile differs so dramatically. However, psychological reliance is always possible with any substance that improves mood or cognition.
Selank and Semax are often called "the Russian peptide twins" because they come from the same research tradition, but they serve different purposes. Selank is primarily anxiolytic (anti-anxiety) and calming, while Semax is more stimulating and cognitive-enhancing — it increases focus, motivation, and mental energy. Both are heptapeptides delivered intranasally, and they're frequently stacked together for a full-spectrum effect: Semax in the morning for focus and drive, Selank throughout the day or evening for calm and emotional balance.
Selank's legal status depends entirely on where you live. In Russia, Ukraine, and several former Soviet states, it is a fully approved prescription medication. In the US, UK, EU, Canada, and Australia, it is not an approved drug and is sold only as a "research chemical" labeled "not for human consumption." Possession for personal research use is generally tolerated but exists in a legal grey zone. It is not currently on the WADA prohibited list for athletes, but this could change, and purity issues from unregulated vendors are a persistent concern.
Selank should not be considered a direct replacement for prescribed anti-anxiety medication without medical guidance, especially for people with clinically diagnosed anxiety disorders, PTSD, or panic disorder. While Russian research shows it produces anxiolytic effects comparable to diazepam, it has not undergone the rigorous multi-phase trials required in the US or EU. Anyone considering using Selank instead of, or alongside, prescription medications should consult a qualified physician — stopping benzodiazepines or SSRIs abruptly can be genuinely dangerous, and Selank is not a substitute for professional mental health care.
